Trevi Therapeutics (TRVI) vs Xencor (XNCR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Xencor (XNCR) has outperformed Trevi Therapeutics (TRVI) over the past year, gaining 88.6% versus a gain of 33.0%. Over five years, TRVI leads with a +922.5% price change compared with -36.0% for XNCR. Trevi Therapeutics is the larger company by market cap ($1.88 billion vs $1.83 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | TRVI | XNCR |
|---|---|---|
| Share price | $13.19 | $24.63 |
| Market cap | $1.88B | $1.83B |
| 1-day change | +2.85% | +0.53% |
| YTD return | +5.35% | +60.88% |
| 1-year return | +32.96% | +88.59% |
| 5-year return | +922.48% | -35.98% |
| EPS (TTM) | $-0.35 | $-2.16 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $125.58M |
| Revenue growth (YoY) | — | +13.65% |
| Net income (latest FY) | $-42.76M | $-91.92M |
| Operating margin | — | -141.35% |
| Net margin | — | -73.20% |
| 52-week high | $20.22 | $30.61 |
| 52-week low | $9.28 | $10.38 |
| Distance from 52-week high | -34.77% | -19.54% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +113.65% | +27.57% |
| Average volume | 2.03M | 1.32M |
| Shares outstanding | 142.48M | 74.35M |
| Employees | 34 | 260 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- XNCR has outperformed TRVI by 55.6 percentage points over the past year.
About Trevi Therapeutics
TRVI stock →Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, and refractory chronic cough. The company develops Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER clinical trial for treatment of chronic cough in patients with IPF, and phase 2a clinical trial in patients with refractory chronic cough.
Health Care · Biotechnology: Pharmaceutical Preparations · 34 employees
About Xencor
XNCR stock →Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of engineered antibodies for the treatment of cancer and autoimmune diseases. The company provides Ultomiris to treat patients with atypical hemolytic uremic syndrome, generalized myasthenia gravis, and neuromyelitis optica spectrum disororder; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.
Health Care · Biotechnology: Pharmaceutical Preparations · 260 employees
TRVI vs XNCR FAQ
Which is bigger, Trevi Therapeutics or Xencor?
Trevi Therapeutics (TRVI) is larger, with a market capitalization of $1.88B compared with $1.83B for Xencor (XNCR).
Which stock has performed better over the past year, TRVI or XNCR?
XNCR returned +88.59% over the past 12 months, compared with +32.96% for TRVI (price return, excluding dividends). Past performance does not predict future results.
Are Trevi Therapeutics and Xencor in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.